This study looked at the use of transurethral microwave thermotherapy (TUMT) for the treatment of benign prostatic hyperplasia (BPH) compared to transurethral resection of the prostate (TURP). It found that both treatments are similarly effective in managing BPH symptoms. TUMT has fewer side effects than TURP, but it also results in an increased need for retreatment.

This study reviewed the initial management of benign prostatic hyperplasia (BPH).  

This study evaluated the effectiveness and safety outcomes of talazoparib (Talzenna) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with mutations in DNA repair genes. The data showed that talazoparib was effective with manageable side effects for these patients.

This study aimed to investigate the link between various treatments for castration-resistant prostate cancer (CRPC) and cognitive (mental) dysfunction in older men. The main finding was that the treatments assessed did not appear to have an impact on cognitive function.

This study assessed the effectiveness of Fluxonorm® herbal supplement when combined with standard therapy for lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH). The authors concluded that the effectiveness of standard therapy was improved by the addition of Fluxonorm® in patients with BPH.

This study evaluated the effect of different surgical interventions on sexual function in patients with benign prostatic obstruction (BPO). The authors concluded that the prostatic urethral lift (PUL) intervention provided significantly improved erectile function at 24 months.

This study compared the effectiveness of docetaxel (DOC; Taxotere) to abiraterone (ABI; Zytiga) and assessed possible predictive markers of progression-free survival (PFS) in patients with metastatic castration-sensitive prostate cancer (mCSPC). The authors concluded that under real-world conditions, ABI was associated with better PFS in these patients.

This study examined the risk of heart-related mortality in patients undergoing androgen-deprivation therapy (ADT) for prostate cancer. It found that patients treated with radiation therapy and ADT did not have an increased risk of heart-related mortality.

This study investigated the effectiveness of RestoreX penile traction device in the treatment of penile complications after prostate surgery. Researchers suggested that RestoreX improves penis length and sexual function after prostate surgery. 

This study compared water vapor thermal therapy using the Rezum system and prostatic urethral lift (PUL) in the treatment of men with urinary symptoms from benign prostatic hyperplasia (BPH). Researchers suggested that both treatments improve symptoms and the quality of life of these patients.